A5039857883- Chronic Myeloid Leukemia Treatments
- Cystic Fibrosis Research Advances
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Health Systems, Economic Evaluations, Quality of Life
- Hepatitis C virus research
- Bacterial Infections and Vaccines
- Venous Thromboembolism Diagnosis and Management
- Tracheal and airway disorders
- Liver Disease Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Child Nutrition and Feeding Issues
- Click Chemistry and Applications
- Neonatal Respiratory Health Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Economic and Financial Impacts of Cancer
- Eosinophilic Disorders and Syndromes
- Fungal Plant Pathogen Control
- Pediatric health and respiratory diseases
- Gastrointestinal Tumor Research and Treatment
- Emergency and Acute Care Studies
Vertex Pharmaceuticals (United States)
2018-2025
Takeda (United States)
2017-2019
Ariadne Diagnostics (United States)
2013-2017
HealthInsight
2011-2014
Optum (United States)
2011-2014
New England College of Optometry
2014
Health Outcomes Solutions (United States)
2006-2011
Health Economics and Outcomes Research (United Kingdom)
2011
GTx (United States)
2011
Cabot (United States)
2010
PspA is a cell surface protein of Streptococcus pneumoniae that present on number clinical isolates as well the nonencapsulated laboratory strain Rx1. In previous report we have shown mAbs directed against can protect mice from at least some pneumococcal strains bearing this protein. our produced insertional inactivation mutants lack and used these to demonstrate play role in virulence anti-PspA immunity lead protection infection. PspA- were obtained using derivatives plasmid pVA891 carrying...
Although there are nearly a quarter of million hospitalizations for traumatic brain injury (TBI) in the United States each year, data on outcomes and costs TBI treatment acute-care setting limited.Using large, geographically diverse, multihospital database, we examined inpatient records persons aged 16 years or older who were hospitalized between January 1, 1997, June 30, 1999. Patients stratified by severity using an adaptation Abbreviated Injury Scale administrative (ICD/AIS), as follows:...
BACKGROUND: Approximately 3.2-3.9 million U.S. residents are infected with the hepatitis C virus (HCV). Total annual costs (direct and indirect) in United States for HCV were estimated to be $5.46 billion 1997, direct medical have been predicted increase $10.7 10-year period from 2010 through 2019, due part increasing number of patients developing advanced liver disease (AdvLD). OBJECTIVE: To quantify a sample commercially insured enrollees (a) total per patient year (PPPY) all-cause payer,...
Abstract Recent research has identified high hepatitis C virus (HCV) prevalence among older U.S. residents who contracted HCV decades ago and may no longer be recognized as risk. We assessed the cost-effectiveness of screening 100% born 1946-1970 over 5 years (birth-cohort screening), compared with current risk-based screening, by projecting costs outcomes remaining lifetime this birth cohort. A Markov model natural history was developed using data synthesized from surveillance data,...
BACKGROUND Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia‐positive (Ph+) acute lymphoblastic (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was compare overall survival (OS) between CML and those Ph+ ALL received ponatinib versus allogeneic stem cell transplantation (allo‐SCT). METHODS A post hoc, retrospective, indirect comparison OS among single‐agent in Ponatinib Evaluation (PACE)...
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in people with cystic fibrosis (CF) ≥ 1 F508del-CFTR allele Phase 3 clinical trials. ELX/TEZ/IVA treatment led improved lung function, increases percent predicted forced expiratory volume second (ppFEV1) Cystic Fibrosis Questionnaire-Revised respiratory domain score. Here, we evaluated the impact of on rate function decline over time by comparing changes ppFEV1 participants from trials a matched group CF US...
To address influenza B lineage mismatch and co-circulation, several quadrivalent inactivated vaccines (IIV4s) containing two type A strains both lineages have recently been approved in the United States. Currently available trivalent (IIV3s) or live attenuated (LAIV3s) comprise one of that co-circulated States since 2001. The objective this analysis was to evaluate cost-effectiveness a policy universal vaccination with IIV4 vs. IIV3/LAIV3 during 1 year On average per season, predicted result...
The Cystic Fibrosis (CF) Impact Questionnaire (CF-IQ) was qualitatively developed to assess the impact of CF in context treatment advancements and increased longevity. This study reports CF-IQ validation. In this noninterventional validation study, people with completed 40-item validating patient-reported outcome measures (PROMs) via electronic diaries at enrollment (baseline) 4-week follow-up. Validation consisted modern methods focus groups finalize structural validity, classical internal...
Background: Reliance on "as-needed" analgesia following total knee arthroplasty may lead to inadequate control of pain and delayed recovery function. Preemptive use controlled-release opioids improve control, accelerate recovery, reduce the need for inpatient rehabilitative services. This study was designed determine whether enhance post-arthroplasty facilitate functional during rehabilitation. Methods: Fifty-nine patients admitted rehabilitation unilateral were randomized receive OxyContin...
Background Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA availability enabled the examination long-term this treatment. This retrospective, longitudinal cohort study investigated impact on mortality rate health among CF US. Methods Data from US Foundation Patient Registry January 2010 December 2019 were analysed. The IVA-treated included a transmembrane conductance regulator ( CFTR ) gating...
Abstract Background Clinical trials have shown low-molecular weight heparin (LMWH) to be at least as safe and efficacious unfractionated (UFH) for preventing venous thromboembolism (VTE) in acutely-ill medical inpatients. Objective To compare clinical economic outcomes among inpatients receiving the LMWH enoxaparin versus UFH prophylaxis practice. Methods Using a large, multi-hospital, US database, we identified persons aged ≥40 years hospitalized ≥6 days an acute condition (including...
Objectives In February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged ≥65 years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding 2010 recommendation for >65 was limited to those with close contact infants. We evaluated clinical economic outcomes adding Tdap booster "baseline" practice [full-strength DTaP administered from 2 months 4–6 years, one at 11–64 replacing decennial Td booster],...
Background Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later ages has not been studied. Methods We conducted an observational cohort study US CF Foundation Patient Registry aged ≥6 years ≥1 transmembrane conductance regulator–gating mutation to compare effects on per cent predicted forced expiratory volume 1 s (ppFEV ) pulmonary exacerbation (PEx) outcomes. People were...
BackgroundTyrosine-kinase inhibitors (TKIs) can be associated with vascular events (VEs). The expected VE rates in patients chronic myeloid leukemia (CML) are unknown. present study examined the event and mortality among elderly without CML.Materials MethodsLinked Surveillance, Epidemiology, End Results cancer registry Medicare claims data were used to identify aged ≥ 66 years an incident (index) diagnosis of CML from 2004 2009. A comparison cohort was matched 1:1 cohort. All followed up 12...
Cystic fibrosis (CF) is a life-limiting genetic disease caused by mutations in the cystic transmembrane conductance regulator (CFTR) gene. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) CFTR modulator (CFTRm) that targets underlying cause of CF. Based on safety and efficacy demonstrated clinical trials, ELX/TEZ/IVA approved US for treatment CF people aged ≥ 2 years who have 1 F508del-CFTR mutation or responsive to based vitro data. While unprecedented improvements lung function dramatic...
Influenza pandemic outbreaks occurred in the US 1918, 1957, and 1968. Historical evidence suggests that majority of influenza-related deaths during 1918 were attributable to bacterial pneumococcal infections. The 2009 novel influenza A (H1N1) outbreak highlights importance interventions may mitigate impact a pandemic. decision-analytic model was constructed evaluate 7-valent conjugate vaccine (PCV7) on disease incidence mortality typical season (13/100) severe (30/100). Outcomes compared for...
Abstract Background Adverse health impacts of cystic fibrosis (CF) can be present in children before respiratory complications are observed. Children with CF show progressive decline, increasing lung function decline adolescence. This study aims to quantify the healthcare resource utilization (HCRU) and costs attributable by comparing general pediatric population. Methods retrospective, cross‐sectional, observational compared HCRU among US demographically similar without (comparison group)...